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Abstract
Hidradenocarcinomas are very uncommon malignant tumors of sweat gland origin that exhibit a high
potential for local recurrence, metastasis, and poor outcome. These neoplasms typically resemble benign
appearing dermal nodules that lack distinguishable features. We present the case of hidradenocarcinoma
in a 39-year-old male with a 5-year history of a slow growing nodule along his right eyebrow. Excisional
biopsy of the lesion was taken with pathology showing nuclear pleomorphism, increased mitoses, and
foci of necrosis. Immunohistochemical analysis revealed reactivity for Ki-67/MIB1 and strong diffuse
staining for p63, CK5/6, and CK7. Mohs micrographic surgery was performed and clear margins were
obtained after one stage. Compared to traditional treatment with wide local excision, Mohs micrographic
surgery is a potentially advantageous alternative therapy as there have been no reported cases of tumor
recurrence or metastasis to date.
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Abstract
Hidradenocarcinomas are very uncommon malignant tumors of sweat gland origin that exhibit a high potential for
local recurrence, metastasis, and poor outcome. These neoplasms typically resemble benign appearing dermal nodules
that lack distinguishable features. We present the case of hidradenocarcinoma in a 39-year-old male with a 5-year history
of a slow growing nodule along his right eyebrow. Excisional biopsy of the lesion was taken with pathology showing
nuclear pleomorphism, increased mitoses, and foci of necrosis. Immunohistochemical analysis revealed reactivity for Ki67/MIB1 and strong diffuse staining for p63, CK5/6, and CK7. Mohs micrographic surgery was performed and clear
margins were obtained after one stage. Compared to traditional treatment with wide local excision, Mohs micrographic
surgery is a potentially advantageous alternative therapy as there have been no reported cases of tumor recurrence or
metastasis to date.
Keywords: Hidradenocarcinoma, Mohs micrographic surgery, Sweat gland tumor

1. Introduction

H

idradenocarcinoma (HAC) is a rare adnexal
neoplasm derived from eccrine sweat glands
with high malignant potential. Historically, HAC
has been reported as having an aggressive clinical
course, with frequent local recurrence ranging from
10 to 50% and a metastatic rate as high as 60%.1e4
The clinical appearance of HAC is nonspeciﬁc,
typically reported as a ﬁrm, solitary, subcutaneous
nodule that is often mistaken clinically for the more
common infundibular and pilar cysts, among other
benign lesions.2 The most frequently affected
anatomic sites include the head and neck. HAC can
be difﬁcult to distinguish from its benign counterpart, hidradenoma, as there are no deﬁnitive histological features or established criteria.
Treatment of choice for HAC has traditionally
been wide local excision, however tumor recurrence
and metastases remain common despite achieving
clinically free margin.3 Furthermore, wide excision

of these tumors can result in large surgical defects
that may pose reconstructive challenge.3 Therefore,
treatment with Mohs micrographic surgery has
been increasingly reported in an attempt to improve
cure rates and aesthetic outcomes.4

2. Case report
A 39-year-old white male presented with a 5-year
history of a ﬂesh-colored nodule along his right
eyebrow. For the past two years the nodule repeatedly increased in size, drained clear ﬂuid, and
subsequently regressed to its original size. The mass
was mildly pruritic, but otherwise asymptomatic.
Past medical history was signiﬁcant for gastroesophageal reﬂux disease. Skin examination
revealed a 1.1  1.1 cm ﬁrm violaceous nodule
(Fig. 1). A sebaceous cyst was initially suspected. An
initial excisional biopsy with 0.1 cm margins and
multilayer linear closure was performed.
Histopathology demonstrated a large, well-circumscribed dermal tumor with solid and cystic
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margin following gentle curetting and then
analyzed with frozen sectioning, which revealed
clear margins. Close follow up has showed no sign
of recurrence.

3. Discussion

Fig. 1. Lesion prior to biopsy. Firm violaceous nodule on the right
eyebrow measuring 1.1  1.1 cm.

growth patterns and abundant ductal differentiation. Focal squamous differentiation at the superﬁcial edge of the tumor was noted. The lesional cells
showed nuclear pleomorphism, scattered single cell
necrosis, small foci of tumoral necrosis, and mildly
increased mitoses (Fig. 2). The borders of the lesion
were predominantly circumscribed rather than
inﬁltrative, although near the superﬁcial edge of the
lesion, in the area of squamous differentiation, some
inﬁltrative features were noted. Immunohistochemical staining was diffusely and strongly positive for p63, CK5/6, and CK7, variably positive for
Ki-67/MIB1, and negative for CEA and HER-2. The
overall morphology and immunoproﬁle of the
lesion was compatible with a hidradenoma, however the presence of nuclear pleomorphism,
increased mitoses, and foci of necrosis are worrisome for malignant hidradenocarcinoma.
The diagnosis and treatment options were discussed. Given the inﬁltrative appearance of this
carcinoma, Mohs micrographic surgery was performed. The stage was removed with a 2 mm

HAC is an uncommon neoplasm of the eccrine
sweat glands that has been associated with high
rates of regional recurrence and metastasis.1e4 The
neoplasm accounts for approximately 6% of malignant eccrine tumors, which are seen in 1 in 13,000
dermatopathology biopsies.5,6 HAC poses a diagnostic challenge given its nondistinctive clinical
appearance and difﬁcultly to distinguish histologically from hidradenoma. The majority of HAC lack
characteristic morphology, with most tumors
prompting a clinical impression of a benign lesion,
as was the case in this patient.3 HAC often presents
as a solitary, ﬁrm, nontender nodule, which may
appear ﬂesh-colored, red, violet, pink, or gray. The
most frequently affected sites include the head and
neck, with lesions on the extremities and trunk
being reported less often.2
Histologic criteria that may be used to distinguish
HACs from hidradenoma include increased mitotic
activity, invasion into surrounding tissue, loss of
circumscription, asymmetry, necrosis, pleomorphism,
dispersed growth pattern, and angiolymphatic or
perineural invasion.2,5 Immunohistochemical staining
is often positive for keratin AE1/3, cytokeratin 5/6, Ki67, and p53. There is no consistent pattern when neoplasms are stained with antibodies to S100 protein,
gross cystic disease ﬂuid protein 15, carcinoembryonic
antigen, epithelial membrane antigen, BCL1, or
BCL2.5,7 In the present case, immunohistochemical
staining was reactive for Ki-67/MIB1 and diffusely
strong for p63, CK5/6, and CK7.
Treatment of HAC has traditionally been
managed with wide local excision, however recurrence and metastatic rates remain higher than
desired, highlighting the need for more effective
options.8 Including our case report, there have been
at least 15 cases of HAC treated using Mohs micrographic surgery.9 To date, there have been no
evidence of recurrence or metastasis in those cases
whom follow up information was available.9 Adjuvant therapies for HAC have included chemotherapy and radiation.2

4. Conclusion
Fig. 2. Hidradenocarcinoma. The lesion showed a well-circumscribed
dermal tumor with nuclear pleomorphism, scattered single cell necrosis,
small foci of tumoral necrosis, and mildly increased mitoses.

https://scholar.rochesterregional.org/advances/vol2/iss2/9
DOI: 10.53785/2769-2779.1102

HAC is an aggressive adnexal tumor that is often
misdiagnosed preoperatively and may beneﬁt from
treatment with Mohs micrographic surgery. While
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the data thus far suggests improved outcomes in
patients treated with Mohs micrographic surgery,
close follow up is still recommended given the
malignant nature of this tumor.
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